FDA Accepts Amgen’s Supplemental New Drug Application For Otezla®...
THOUSAND OAKS, Calif., May 5, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application...
View ArticleAmgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
THOUSAND OAKS, Calif., May 10, 2021 —Amgen (NASDAQ: AMGN) today announced its partner AstraZeneca (NASDAQ: AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration...
View ArticleClik here to view.
Amgen Announces New Data Being Presented At ASH 2021
BLINCYTO® (blinatumomab) Data Demonstrate Superior Overall Survival in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia in Longer Follow-up of Phase 3 Trial First Presentation of Efficacy...
View ArticleClik here to view.
Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to...
THOUSAND OAKS, CA & WALTHAM, MA – Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against...
View ArticleClik here to view.
Lumakras® (Sotorasib) Codebreak 100 Study Shows Two-Year Overall Survival Of...
Long-Term Clinical Benefit and Prolonged Tumor Response Seen With 40.7% Objective Response Rate No New Safety Signals Observed Longest Follow-Up of Patients Treated With a KRASG12C Inhibitor THOUSAND...
View ArticleClik here to view.
Amgen Presents New Tarlatamab Clinical Data at WCLC 2022
Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Third-line...
View ArticleClik here to view.
New Amgen Data at Esc 2022 Show Long-Term Ldl-C Lowering With Repatha®...
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented...
View ArticleClik here to view.
Lumakras® (Sotorasib) Combined with Vectibix® (Panitumumab) Shows Confirmed...
Phase 1b Results Demonstrate Encouraging Median Progression-Free Survival of 5.7 Months in Difficult-to-Treat Patient Population THOUSAND OAKS, CA — Amgen (NASDAQ: AMGN) today announced updated data...
View ArticleClik here to view.
Amgen British Columbia Completes State of the Art Lab Expansion
BURNABY, BC – Amgen, one of the world’s leading biotechnology companies, announced the completion of a 4500 square foot expansion, capping off a $27 million investment in its state-of-the-art Canadian...
View Article
